[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575574":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":42,"locations":50,"responsibleParty":94,"collaborators":97,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":10,"enrollmentInfo":113,"targetDuration":10,"studyType":116,"phases":10,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: Cohort of Transgender and Gender Diverse individuals in Switzerland",null,"Individuals who present before they start GAHT are included in group A",[13],"Other: Group A (start of GAHT)",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B: Cohort of Transgender and Gender Diverse individuals in Switzerland","Individuals who are already on GAHT are included in group B",[18],"Other: Group B (on-going GAHT)",{"label":20,"type":10,"description":21,"interventionNames":22},"Group C: Cohort of Transgender and Gender Diverse individuals in Switzerland","Individuals who undergo gender affirming surgery are (additionally or exclusively) included in group C",[23],"Other: Group C (GAS)",[25,29,33],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Group A (start of GAHT)","The study program consists of assessments at baseline (before the start of GAHT) and subsequent follow-up visits scheduled at routine intervals which are typically every three months for the first year, every six months for the second year and every twelve months thereafter. Participants' data collection includes a mix of digital and in-person methods. Demographical information, clinical and laboratory parameters such as hormone levels which are part of standard clinical care",[9],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Group B (on-going GAHT)","The study program consists of a yearly assessment as part of the long-term routine follow-up. Participants' data collection includes a mix of digital and in-person methods. Demographical information, clinical and laboratory parameters such as hormone levels which are part of standard clinical care",[15],{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"Group C (GAS)","If GAS is administered, additional assessments are performed preoperatively, and postoperatively in analogy with routine clinical visits, e.g. one week after surgery and then three, six and twelve months later (then once yearly) (e.g. type of surgery, outcome, patient' satisfaction). If participants undergo gender-affirming genital surgery, a genital swab and urine analysis (from the urine sample taken for routine testing) will additionally be performed for microbiome analyses as part of the study assessment.",[20],[38],{"name":39,"affiliation":40,"role":41},"Bettina Winzeler, PD Dr.","University Hospital Basel, Department of Endocrinology","PRINCIPAL_INVESTIGATOR",[43,47],{"name":39,"role":44,"phone":45,"phoneExt":10,"email":46},"CONTACT","+41 61 556 50 75","bettina.winzeler@usb.ch",{"name":48,"role":44,"phone":10,"phoneExt":10,"email":49},"Hüseyin Cihan, Dr.","hueseyin.cihan@usb.ch",[51,67,82],{"facility":52,"status":53,"city":54,"state":10,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"University Hospital of Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":59,"coordinates":60},"Point",[61,62],7.57327,47.55839,{"lat":62,"lon":61},[65],{"name":66,"role":44,"phone":45,"phoneExt":10,"email":46},"Bettina Winzeler, PD Dr. med.",{"facility":68,"status":69,"city":70,"state":10,"zip":71,"country":56,"countryCode":57,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Cantonal Hospital of Lucerne","NOT_YET_RECRUITING","Lucerne","6000",{"type":59,"coordinates":73},[74,75],8.30635,47.05048,{"lat":75,"lon":74},[78],{"name":79,"role":44,"phone":80,"phoneExt":10,"email":81},"Lea Slahor, KD Dr.","+41 205 51 03","lea.slahor@luks.ch",{"facility":83,"status":69,"city":84,"state":10,"zip":85,"country":56,"countryCode":57,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"University Hospital of Zürich","Zurich","8091",{"type":59,"coordinates":87},[88,89],8.55,47.36667,{"lat":89,"lon":88},[92],{"name":66,"role":44,"phone":93,"phoneExt":10,"email":46},"+41 44 255 36 20",{"type":41,"investigatorFullName":95,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Bettina Winzeler","PD Dr.",[98,100],{"name":99,"class":6},"University Hospital, Zürich",{"name":101,"class":102},"Cantonal Hospital Lucerne, Switzerland","UNKNOWN","100575574","swiss-prospective-cohort-of-transgender-and-gender-diverse-individuals---the-spectra-study-100575574",false,"NCT06774053","Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","Swiss Prospective Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","SPECTRA","Inclusion Criteria:\n\n* Age 16 years and above.\n* Established diagnosis of gender incongruence\n* Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Missing commitment or ability to study protocol adherence","ALL","16 Years",{"count":114,"type":115},600,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.\n\nThe main question is:\n\nWhat are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?\n\nResearchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.\n\nParticipants will:\n\nComplete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.\n\nProvide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.\n\nUndergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.",[119,120],"Transgender Individuals","Gender Incongruence",[122,123,124],"Gender Affirming Hormone Therapy (GAHT)","Gender Affirming Surgery (GAS)","Transgender and Gender Diverse (TGD)","2026-06-26",{"date":127,"type":128},"2026-06-30","ACTUAL",{"date":130,"type":128},"2026-04-20",{"date":132,"type":115},"2046-01",{"name":5,"class":6},3]